Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Net sales	$ 3,738.0	$ 3,933.9	$ 11,177.4	$ 11,562.5
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,362.2	2,533.1	7,034.4	7,398.1
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,375.8	1,400.8	4,143.0	4,164.4
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	375.6	381.6	1,112.9	1,179.5
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	168.9	175.5	507.1	560.6
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	129.9	141.7	368.4	423.1
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	123.2	131.9	318.9	355.2
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	100.2	110.5	307.0	336.5
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	84.6	77.5	237.8	224.3
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	74.1	84.7	218.5	255.5
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	66.3	65.5	188.4	194.9
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	60.6	62.7	177.5	173.7
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	41.2	47.9	129.3	145.0
Influvac ®
Disaggregation of Revenue [Line Items]
Net sales	121.3	137.2	126.0	137.5
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	62.2	58.3	171.9	160.3
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	43.5	44.1	146.7	155.0
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	38.6	28.2	108.5	119.7
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	38.2	37.7	108.1	115.8
Developed Markets Segment | Brands
Disaggregation of Revenue [Line Items]
Net sales	1,217.6	1,391.3	3,630.2	3,923.5
Developed Markets Segment | Generics
Disaggregation of Revenue [Line Items]
Net sales	1,081.1	1,017.2	3,153.1	3,009.2
Greater China | Brands
Disaggregation of Revenue [Line Items]
Net sales	559.4	546.5	1,636.9	1,639.4
Greater China | Generics
Disaggregation of Revenue [Line Items]
Net sales	2.4	1.9	7.8	5.7
Japan, Australia and New Zealand Segment | Brands
Disaggregation of Revenue [Line Items]
Net sales	189.3	185.7	571.8	583.4
Japan, Australia and New Zealand Segment | Generics
Disaggregation of Revenue [Line Items]
Net sales	155.0	148.8	439.9	468.8
Emerging Markets Segment | Brands
Disaggregation of Revenue [Line Items]
Net sales	395.9	409.6	1,195.5	1,251.8
Emerging Markets Segment | Generics
Disaggregation of Revenue [Line Items]
Net sales	137.3	232.9	542.2	680.7
Operating Segment | Developed Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	2,298.7	2,408.5	6,783.3	6,932.7
Operating Segment | Greater China
Disaggregation of Revenue [Line Items]
Net sales	561.8	548.4	1,644.7	1,645.1
Operating Segment | Japan, Australia and New Zealand Segment
Disaggregation of Revenue [Line Items]
Net sales	344.3	334.5	1,011.7	1,052.2
Operating Segment | Emerging Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 533.2	$ 642.5	$ 1,737.7	$ 1,932.5